NasdaqGS:HALOBiotechs
Is Takeda ENHANZE Deal on Vedolizumab Reshaping the Investment Case for Halozyme Therapeutics (HALO)?
In December 2025, Halozyme Therapeutics announced a global collaboration and exclusive license agreement granting Takeda access to its ENHANZE drug delivery technology, including rights to use recombinant human hyaluronidase PH20 with vedolizumab for inflammatory bowel disease, in exchange for an upfront payment, potential milestones, and low- to mid-single-digit royalties.
This deal extends ENHANZE into a widely used biologic therapy for Crohn’s disease and ulcerative colitis, potentially...